Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JD002 in r/r AML after allo-HSCT
NCT05744440Phase 1Unknown
- Sponsor
- Xuzhou Medical University
- Start
- Mar 2023
- Primary completion
- May 2025
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JD002 in acute myeloid leukemia (AML), sponsored by Xuzhou Medical University. Primary endpoints: Dose-limiting toxicities at 1 month and Objective Response Rate at 3 months. Status: unknown.
02
Drugs
JD002
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05744440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744440.